Genotyping News and Research

RSS

IMPAKT 2011 conference to highlight new breast cancer studies

"The presentations at this year's IMPAKT reveal the innovative and diverse approaches that investigators are taking to identify the most encouraging new agents both before clinical evaluation and in early clinical studies. These range from ideas for novel clinical designs to the development of more sensitive and specific biomarkers and to data sharing that allows a more objective assessment of compounds prior to commitment of major clinical resources."

30 Apr 2011

Roche's cobas HPV Test receives FDA approval for cervical cancer screening

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may prevent many women from developing this deadly disease.

From Roche Sequencing and Life Science 20 Apr 2011

Study links genes with alcohol consumption among Asians

In a study of 1,721 Korean male drinkers aged 40󈞱 y in an urban population-based cohort, and another sample of 1,113 male drinkers from an independent rural cohort, information on average daily alcohol consumption was collected and DNA samples were collected for genotyping.

31 Mar 2011

Roche launces new GS GType HLA Primer Sets for HLA genotyping

454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS GType HLA Primer Sets for high- and medium-resolution genotyping of class I and class II loci of the Human Leukocyte Antigen (HLA) genes.

30 Mar 2011

Researchers identify enzyme biomarker that can diagnose early colon cancer

A research team at the University of Colorado Cancer Center has identified an enzyme that could be used to diagnose colon cancer earlier. It is possible that this enzyme also could be a key to stopping the cancer.

28 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011

Celera reports net revenue of $34.9 million for fourth quarter of 2010

Celera Corporation today reported net revenues of $34.9 million for the fourth quarter of 2010 that ended December 25, 2010, compared to $39.2 million for the prior year quarter.

18 Mar 2011

Study to identify drug targets for rheumatoid arthritis patients not responding to anti-TNF therapies

GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced the publication of results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies.

11 Mar 2011

ALR commits funding for new study to identify lupus susceptibility genes in multiple ethnicities

The Alliance for Lupus Research (ALR) – the world's largest private funder of lupus research – today announced funding of an important new study to identify lupus susceptibility genes in multiple ethnicities including African Americans, who are three times more likely than Caucasians to have the disease.

10 Mar 2011

Fluidigm fourth quarter revenue increases to $10.4 million

Fluidigm Corporation today announced its financial results for the fourth quarter and full year ended December 31, 2010.

9 Mar 2011

RainDance, 454 Life Sciences collaborate to launch core ADME gene screening research panel

RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company, today announced a collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution for the simple and cost-effective investigation of drug absorption, distribution, metabolism, and excretion (ADME).

9 Mar 2011

Ambry, RainDance enter new collaboration to develop and commercialize ADME screening

RainDance Technologies, Inc. and Ambry Genetics, today announced a new collaboration focused on the development and commercialization of a comprehensive drug absorption, distribution, metabolism, and excretion genetic screening panel for use on next-generation sequencing systems.

8 Mar 2011

Scientists discover SNPs linked with high risk of sick sinus syndrome

Scientists at deCODE genetics and academic colleagues from Iceland, The Netherlands, Denmark, USA and Illumina, Inc., today report the discovery of single-letter variants in the sequence of the human genome associated with high risk of sick sinus syndrome.

6 Mar 2011

Affymetrix releases complete genotyping data set on its website

Affymetrix, Inc. today announced the release of a complete data set of 5 million variants on its website.

3 Mar 2011

Scripps Health offers genetic testing to patients with Hepatitis C

Scripps Health is one of the first health systems in the United States to offer genetic testing as part of its care for hepatitis C patients planning to undergo drug treatment.

28 Feb 2011

Study demonstrates ability of cobas HPV Test to detect HPV-16, HPV-18 genotypes linked to cervical cancer

Roche announced that a study published online today in the American Journal of Clinical Pathology demonstrated the ability of the cobas HPV Test to individually detect HPV-16 and HPV-18, two of the highest risk HPV genotypes causing 70 percent of cervical cancer cases.

From Roche Sequencing and Life Science 25 Feb 2011

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

Macrogen announces formation of Axeq Technologies in the US, Europe and Asia

Macrogen, Inc announces the formation of Axeq Technologies, a US-based division with operations and offices in the US, Europe and Asia. "Axeq" is a premium brand representing a whole new experience and industry-leading standards in DNA sequencing service.

22 Feb 2011

Researchers develop new DNA test for accurate detection of Turner syndrome in children

As a child grows, a short stature is not usually cause for concern, but it is often the only sign of a condition called Turner syndrome. Prevalent in girls, Turner syndrome is a genetic defect that short-circuits normal growth and leads to cardiac and renal problems. It is not commonly detected until age 10 or older when a youngster's unusually short height raises suspicions.

16 Feb 2011

WaferGen offers SNP Genotyping screening with new SmartChip PCR System

WaferGen Biosystems, Inc. a leading developer of state-of-the-art genomic analysis systems, today announced that it is offering an early access program for high-throughput Single Nucleotide Polymorphism Genotyping through its new SmartChip Real-Time PCR System.